Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom

Journal of Allergy and Clinical Immunology

Volumn 101, Issue 6 II, 1998, Pages 747-754

  Müller, Ulrich ^a   Akdis, Cezmi A ^b   Fricker, Michael ^a   Akdis, Mübeccel ^b   Blesken, Thorsten ^b   Bettens, Florence ^c   Blaser, Kurt ^b  

^a Spital Netz Bern   (Switzerland)

^b SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anergy; Bee sting allergy; Bee venom phospholipase A2; Immunotherapy; T cell epitopes

Indexed keywords

BEE VENOM; EPITOPE; T LYMPHOCYTE ANTIGEN;

ADULT; ALLERGENICITY; ANAPHYLAXIS; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CLONAL ANERGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; INSECT ALLERGY; MALE; PRIORITY JOURNAL; PROVOCATION TEST; T LYMPHOCYTE;

EID: 0031866059     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(98)70402-6     Document Type: Article

References (42)

1. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-35.
2. Wallner G, Gefter M. Immunotherapy with T cell-reactive peptides derived from allergens. Allergy 1994;49:302-8.
3. Wraith D. Induction of antigen-specific unresponsiveness with synthetic peptides: SIT for treatment of allergic and autoimmune conditions. Int Arch Allergy Immunol 1995;108:585-9.
4. Norman PS, Ohmann JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623-8.
5. Briner T, Kuo M, Keating K, Rogers B, Greenstein J. Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993;90:7608-12.
6. Hoyne G, O'Hehir RE, Wraith D, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993;178:1783-8.
7. Sobotka A, Franklin R, Adkinson F, Valentine M, Baer H, Lichtenstein L. Allergy to insect stings II. Phospholipase A2: the major allergen in honeybee venom. J Allergy Clin Immunol 1976;57:29-40.
8. Müller U, Dudler T, Schneider T, Crameri R, Fischer H, Skrbic D, et al. Type I skin reactivity to native and recombinant phospholipase A2 from honey bee venom is similar. J Allergy Clin Immunol 1995;96:395-402.
9. Aalberse RC, van der Gaag R, van Leuwen J. Serologic aspects of IgG4 Abs. I. Prolonged immunization results in an IgG4 restricted response. J Immunol 1983;130:722-6.
10. 2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells. J Allergy Clin Immunol 1997;99:345-53.
11. Müller U. Epidemiology of insect sting allergy. Epidemiology of clinical allergy. Monogr Allergy 1993;31:131-46.
12. Carballido JM, Carballido-Perrig N, Kägi MK, Meloen RH, Wüth-rich B, Heusser CH, et al. T cell epitope specificity in human allergic and non-allergic subjects to bee venom phospholipase A2. J Immunol 1993;150:3582-91.
13. Dudler T, Altmann F, Carballido JM, Blaser K. Carbohydrate-dependent, HLA Class II-restricted, human T cell response to the bee venom allergen phospholipase A2 in allergic patients. Eur J Immunol 1995;25:538-42.
14. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Müller U, et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:1676-83.
15. Dudler T, Chen WQ, Wang S, Schneider T, Annana RR, Dempey RO, et al. High-level expression in Escherichia coli and rapid purification of enzymatically active honey bee venom phospholipase A2. Biochim Biophys Acta 1992;1165:201-10.
16. Skrbic D, Fischer H, Piatrch D, Jutel M, Müller U. Ultra-Rush Hyposensibilisierung bei Bienengiftallergie. Allergologie 1996;19:123-9.
17. Weeks I, Woodhead JS. Chemiluminescence Immunoassay. J Clin Immunoassay 1984;7:82-9.
18. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameter of production and a quantitative microassay for activity. J Immunol 1978;120:2027-32.
19. Rieben R, Blaser K. Quantification of IgG and IgG4 antibodies to bee venom phospholipase A2 by inhibition ELISA. J Immunol Methods 1989;119:1-8.
20. Held W, Stucki M, Heusser CH, Blaser K. Production of human antibodies to bee venom phospholipase A2 in vitro. Scand J Immunol 1989;29:203-9.
21. Schneider T, Lang AB, Carballido JM, Santamaria LF, Dudler T, Kägi MK, et al. Human monoclonal and polyclonal antibodies recognize predominantly discontinuous epitopes on bee venom phospholipase A2. J Allergy Clin Immunol 1994;94:61-9.
22. lck and ZAP 70 tyrosine kinase activities. J Immunol 1997;159:53-60.
23. Müller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445-80.
24. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldman M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983;157:1434-7.
25. Jutel M, Pichler W, Skrbic D, Urwyler A, Dahinden C, Müller U. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen stimulated T cell cultures. J Immunol 1995;154:4187-94.
26. + T cells from allergic individuals. J Exp Med 1993;178:2123-30.
27. Varney V, Hamid Q, Gaga M, Ying S, Jacobson M, Frew A, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen induced late phase cutaneous responses. J Clin Invest 1993;92:644-51.
28. Litwin A, Pesce JA, Micheal JG. Regulation of the immune response to allergens by immunosuppressive allergenic fragments I. Peptic fragments of honey bee venom phospholipase A2. Int Arch Allergy Immunol 1988;87:361-6.
29. Gammon G, Sercarz EE, Benichou G. The dominant self and the cryptic self: shaping the autoreactive T cell repertoire. Immunol Today 1991;12:193-5.
30. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscous recognition by T cells. Eur J Immunol 1989;19:2237-42.
31. Carballido JM, Carballido-Perrig N, Heusser CH, Blaser K. Regulation of the cytokine production of allergen-specific human T cell clones by the allergen. Int Arch Allergy Immunol 1992;99:366-9.
32. Carballido JM, Carballido-Perrig N, Terres G, Heusser CH, Blaser K. Bee venom phospholipase A2-specific T cell clones from human allergic and non-allergic individuals: cytokine patterns change in response to the antigen concentration. Eur J Immunol 1992;22:1357-63.
33. Blaser K. T cell and B cell epitopes in bee venom phospholipase A2: antigen-dose dependent cytokine ratios regulate specific IgE and IgG antibody responses. In: Schneider CH, editor. Peptides in Immunology. New York: D. Wiley & Sons; 1996. p. 93-101.
34. Carballido JM, Faith A, Carballido-Perrig N, Blaser K. The intensity of T cell receptor engagement determines the cytokine pattern of human allergen-specific T helper cells. Eur J Immunol 1997;27:515-21.
35. Blaser K. Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production. In: Sehon A, HayGlass KT, Kraft D, editors. Advances in experimental medicine and biology. New York: Plenum Press; 1996. p. 295-303.
36. Carballido JM, Carballido-Perrig N, Oberli-Schrämmli A, Heusser CH, Blaser K. Regulation of IgE and IgG4 responses by allergen specific T cell clones to bee venom phospholipase A2 in vitro. J Allergy Clin Immunol 1994;93:758-67.
37. Müller U, Mosbech H. Position paper: immunotherapy with Hymenoptera venoms. Allergy 1993;48(Suppl 14):36-46.
38. Jutel M, Skrbic D, Pichler W, Müller U. Ultra-rush bee venom immunotherapy does not reduce cutaneous weal responses to bee venom and codeine phosphate. Clin Exp Allergy 1995;25:1205-10.
39. Hunt K, Valentine M, Sobotka A, Benton A, Amodio F, Lichtenstein L. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-61.
40. Jutel M, Müller U, Fricker M, Rihs S, Pichler W, Dahinden C. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 1996;26:1112-8.
41. Schleimer RP, Derse CP, Friedmann B, Gillis S, Flaut M, Lichtenstein ML, et al. Regulation of human basophil mediator release by cytokines. I. Interaction with anti-inflammatory steroids. J Immunol 1989;143:1310-7.
42. Brunner T, Heusser CH, Dahinden CA. Human peripheral blood basophils primed by IL-3 produce IL-4 in response to IgE receptor stimulation. J Exp Med 1993;177:605-11.